Ontology highlight
ABSTRACT: Importance
Biological therapies have revolutionized inflammatory bowel disease management, but many patients do not respond to biological monotherapy. Identification of likely responders could reduce costs and delays in remission.Objective
To identify patients with Crohn disease likely to be durable responders to ustekinumab before committing to long-term treatment.Design, setting, and participants
This cohort study analyzed data from 3 phase 3 randomized clinical trials (UNITI-1, UNITI-2, and IM-UNITI) conducted from 2011 to 2015. Participants (n = 401) were individuals with active (C-reactive protein [CRP] measurement of ≥5 mg/L at enrollment) Crohn disease who received ustekinumab therapy. Data analysis was performed from November 1, 2017, to June 1, 2018.Exp
SUBMITTER: Waljee AK
PROVIDER: S-EPMC6512283 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature